Shares of Ocular Therapeutix (OCUL) have gained 5.7% over the past four weeks to close the last trading session at $8.03, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.89 indicates a potential upside of 85.4%. The mean estimate comprises nine short-term price targets with a standard deviation of $3.30. While the lowest estimate of $11 indicates a 37% increase from the curr ...